A reader-funded review of treatments, supplements & cutting-edge wellness · Issue No. 14 · May 2026
Vol. III · The Longevity Issue

A diary of what
actually works.

Independent, evidence-led reviews of GLP-1s, peptides, infusions and aesthetic procedures, written for women who want the study notes before the sponsored post.

7Published reviews
14Evidence dimensions
0Brand sponsorships
Woman walking outside with coffee in soft morning light
Issue No. 14 cover story

“The Tirzepatide diaries: what the before-and-after posts leave out.”


The Briefing
This week
in glow.
Updated · 02 May 2026
Peer-reviewed

Semaglutide vs. Tirzepatide: a 36-week head-to-head.

Mean BMI loss, lean-mass preservation, lipid panels and the side-effect curve nobody charts honestly.

Emerging

Epitalon: the longevity peptide that won't quit the headlines.

Old research, modern protocols, and why telomere language can sound more settled than the evidence actually is.

Emerging clinical

Polynucleotide salmon DNA injectables, audited.

What early dermatology data and patient photos suggest: texture looks more plausible than lift, and the word “regenerative” needs a haircut.

№ 01

The Cover Review

May 2026 · A 12-minute read

Tirzepatide, after the hype.
A−
The Glow Verdict
Strong evidence for indicated patients; not a casual wellness shortcut.

Tirzepatide, after the hype.

The uncomfortable parts of the GLP-1 boom that rarely make it into glossy before-and-afters: tolerance, muscle retention, cost, access, and what happens when treatment stops.

Efficacy9.1 /10
Safety profile7.4 /10
Cost-to-benefit6.8 /10
Evidence base9.6 /10
Read the full review →By Dr. Lina Park · Last reviewed 28 Apr 2026
№ 02

The Index

7 reviews · Updated weekly

AllGLP-1 & GIPPeptidesHormonesSkincare activesAesthetic proceduresSleep & recovery
№ 03

The Glow Index

Q2 2026 standings · By Glow Verdict score

01TirzepatideGLP-1/GIPPhase IIIA−
02SemaglutideGLP-1Phase IIIA−
03Estradiol patchHRTMatureB+
04TretinoinRetinoidMatureA